Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting

NCT02150499 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT02150499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02150499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2014
Completion date
December 31, 2014
Enrollment
18 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

asthma